Fundraising Fox
6 Dimensions Capital
Venture capitalGrand Cayman · Seed–Late Stage · 17 people tracked
Also known as 6 DIMENSIONS CAPITAL LIMITED · FRONTLINE BIOVENTURES (HONG KONG) LIMITED · Wuxi Healthcare Ventures · WUXI HEALTHCARE VENTURES MANAGEMENT US LLC
Find your way into 6 Dimensions Capital
Each arrow is one introduction. Sign up to fill in the first one.
Ask Meera Clark to introduce you to Nan Li
You →Meera · together at Obvious Ventures →Nan
Ask Jamie Chen to introduce you to Wei Li
You →Jamie · together at Quantxbio →Wei
Ask Sam Okafor to introduce you to Hannes Smarason
You →Sam · together at Icelandair →Hannes
- Rebecca Zhu256 people can intro you
- Colin Wang191 people can intro you
- Leyi Wang191 people can intro you
Sign up to find every way you can get introduced to 6 Dimensions Capital
- Your email: who you already know at 6 Dimensions Capital, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the 6 Dimensions Capital team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
6 Dimensions Capital is a healthcare-focused investment firm with offices in Boston, San Francisco, Hong Kong, and Shanghai. It backs healthcare startups and growth-stage companies operating in the U.S., Europe, China, Israel, and other markets, with an emphasis on life sciences businesses spanning China and the United States.
Source: firm website, verified Sep 29, 2026.
Team · 17 people
from curated & public directories
Founder mafia
3 people who came through 6 Dimensions Capital went on to found or lead other companies.
What they invest in
from 20 of 26 portfolio companiesBiotech ×18Healthtech ×11AI & Machine Learning ×10Deep Tech ×6Medical Devices ×6SaaS ×5Digital Health ×3Enterprise Software ×2
HQs:United States×14Canada×1China×1United Kingdom×1
Investments · 26 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 52023 · 12022 · 12021 · 22020 · 12019 · 22018 · 92017 · 224 dated
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inJosh Ofman(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)in
Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu Ventures+13 more
-2.png)
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures Fund+7 more
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inAmeet Nathwani, M.D.(Executive Officer, Director)in
Co-investorsARCH Venture PartnersEcoR1 CapitalGeneral CatalystSamsara BioCapitalInnovation EndeavorsLeaps by Bayer+6 more
.png)
A company focused on developing clinical treatments aimed at improving patient outcomes.
BiotechHealthtechMedical DevicesBoston, US
David Southwell(Executive Officer, Director)inRobert Crane(Executive Officer)
BoardLea Hachigian(Director)Steve Kraus(Director)inCampbell Murray(Director)in
Board seatHannes Smarason· per SEC Form D · $23.3M raise · filed Jul 2019
Co-investorsAstellas Venture Management LLCBessemer Venture PartnersGV (Google Ventures)Longwood FundRA CapitalPitango
AnchorDx develops, manufactures, and sells cancer early-screening and diagnostic products based on ctDNA methylation high-throughput sequencing, along with related testing services covering over 70% of high-incidence cancers such as lung, breast, digestive, and urinary cancers.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesGuangzhou, CN
范建兵(Founder)
Co-investorsMarathon Venture PartnersOrbiMed
Aspect Biosystems develops bioprinted tissue therapeutics using a platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and biomaterials to create implantable allogeneic tissues.
AI & Machine LearningBiotechLongevity
Tamer Mohamed(Founder & CEO)inSam Wadsworth(Co-founder & Chief Scientific Officer)inSimon Beyer(Co-founder & Chief Technology Officer)inLeela Paris(Chief Technical Operations Officer)inMike Scott(Chief Development Officer)inRay Smith(Chief Financial Officer)in
Co-investorsAngel ForumCivilization Ventures Management, LlcInBC Investment Corp.JDRF T1D FundPage One VenturesPallasite Ventures+6 more
Automata provides lab automation and data management tools, enabling researchers and technicians to generate accurate data at scale through intuitive workflow creation.
Advanced ManufacturingAI & Machine LearningDeep TechHardwareHealthtechLegalTechRoboticsSaaSLondon, GB
Mostafa ElSayed(CEO and Co-Founder)inSuryansh Chandra(Co-Founder)
Co-investorsAir Street CapitalBlue Wire CapitalEntrepreneur FirstHCVCHummingbird VenturesIn-Q-Tel+12 more
Hong Kong-listed (2137.HK) biotech founded in 2018 developing infectious disease therapies, led by hepatitis B functional-cure programs.
Co-investorsARCH Venture PartnersBlue Pool CapitalBoyu CapitalSequoia Capital
Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development.
BiotechHealthtechBaltimore, US
James N. Campbell(President, Chief Scientific Officer)inKerrie L. Brady(Executive Officer)inGregg Beloff(Executive Officer)Jeffrey B. Kindler(Chief Executive Officer)inCharles Oh(Chief Medical Officer)inSmital Shah(Acting CBO)in
Co-investorsCatalio Capital Management, LPEFung CapitalNew Enterprise Associates (NEA)Quan CapitalAvoro Capital AdvisorsExome Asset Management
Convoke offers an AI platform that ingests and structures data from documents, scientific literature, SEC filings, and clinical data, and deploys custom agents to automate knowledge tasks and generate reports, manuscripts, and landscape analyses.
AI & Machine LearningBiotechEnterprise SoftwareHealthtechSaaS
Co-investorsAudaciousKleiner PerkinsACMEComma CapitalDimension CapitalLux Capital+2 more
Hong Kong-listed (HKEX: 2616) Chinese biopharmaceutical company developing oncology, immunology and inflammation therapies.
Co-investorsARCH Venture PartnersBoyu CapitalGICHillhouse CapitalWuXi Healthcare Ventures
Fiveonefour builds tooling focused on agent experience (AX), helping developers ship software that AI agents can use effectively.
AI & Machine LearningDeveloper ToolsSaaSPortland, US
Timote Gelinas Delisle(Executive Officer, Director, Promoter)Chris Crane(Founder)inNicolas Joseph(Founder)in
BoardNan Li(Director)in
Co-investorsFlybridge Capital PartnersMaterialized View CapitalVermilion Cliffs VenturesDimension CapitalRidge VenturesStage 2 Capital
Frontera Therapeutics is a biotechnology company engaged in therapeutic research and development, spanning translational medicine, clinical operations, and manufacturing.
BiotechDeep TechHealthtechBoston, US
Xinyan Li(CEO)
Co-investorsOrbiMedBoyu CapitalCreacion VenturesHongShan Capital Group
HiberCell develops therapeutic candidates targeting the Integrated Stress Response pathway to address treatment-resistant cancers, relapse, and metastasis.
BiotechMedical Devices
Julio Aguirre-Ghiso, Ph.D.(Co-Founder)
Co-investorsARCH Venture PartnersMagnetic VenturesRaptor GroupHercules Capital, Inc.Hillhouse Capital
Shanghai-based, HKEX-listed drug developer commercializing dorzagliatin, the first approved glucokinase activator for type 2 diabetes.
Co-investorsARCH Venture PartnersF-Prime CapitalVenrockAlly Bridge GroupBlue Pool CapitalEight Roads Ventures+2 more
Iterative Health is a healthcare technology and services company that combines clinical trial expertise with AI to help research teams and study sponsors expand and speed up patients' access to novel therapeutics.
AI & Machine LearningBiotechHealthtechCambridge, US
Jonathan Ng(Executive Officer, Director)in
BoardPeter Moran(Director)Nan Li(Director)inCharles Cooney(Director)
Co-investorsAlumni VenturesBreyer CapitalG Vision CapitalGV (Google Ventures)IKJ CapitalInsight Partners+12 more
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)in
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in
Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess Fund+8 more
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
BiotechCambridge, US
Robert Millman(Executive Officer, Director)
BoardTodd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)
Co-investorsARCH Venture PartnersF-Prime CapitalJDRF T1D FundORI CapitalSlater Technology FundCowen Healthcare Investments+4 more
Tamarind provides a computational platform for protein and molecular engineering, offering AI and physics-based tools to design antibodies, peptides, enzymes, and small molecules.
AI & Machine LearningBiotechDeep TechEnterprise SoftwareSaaSSan Francisco, US
Deniz Kavi(Co-founder & CEO)inSherry Liu(Founder)in
Co-investorsTranspose Platform ManagementTreeo VCY Combinator468 CapitalDimension CapitalEight Capital+2 more
Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)Rob Carson(Chief Executive Officer)inSimona Levi(Chief Legal Officer)in
Co-investorsARCH Venture PartnersNorthpond VenturesAlly Bridge GroupApplied VenturesKilonova CapitalPura Vida Investments+3 more
Unity Biotechnology was a biotechnology company that is no longer operating.
BiotechBrisbane, US
Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in
Co-investorsage1Alumni VenturesARCH Venture PartnersCycad Group LLCEcoR1 CapitalKhosla Ventures+6 more
Verisian builds software for clinical research and public health authorities to analyze and monitor clinical trial data in real-time, improving decision-making and trial safety.
BiotechDigital HealthHealthtechSaaS
BoardSunil Gupta(Strategic Advisor)
Co-investorsCambridge Angels groupRecode VenturesSuperSeedManchesterStory Group, LLC
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Erasca TxIgnis TherapeuticsiTeos TherapeuticsViela Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 7
5 IPOs · 2 acquisitions · showing 3GrailNASDAQ: GRALKymera TherapeuticsNASDAQ: KYMRSemma Therapeuticsacq. by Vertex Pharmaceuticals
Portfolio news
latest coverage across their companiesIterative Health · finsmes.com · Apr 30, 2026
Centrexion Therapeutics · trysignalbase.com · Mar 25, 2026
Automata · finsmes.com · Jan 29, 2026
Fiveonefour · prnewswire.com · Sep 4, 2025
Convoke · finsmes.com · Aug 20, 2025
Frequently asked questions
- How many investments has 6 Dimensions Capital made?
- 6 Dimensions Capital has 26 tracked investments, 7 of which have exited, including 6 dated in the last 24 months.
- What stage does 6 Dimensions Capital invest at?
- 6 Dimensions Capital invests at the Seed, Series A, Series B, Growth, Late Stage stages.
- What sectors does 6 Dimensions Capital focus on?
- 6 Dimensions Capital focuses on Biotech, Healthtech, Medical Devices, New Materials.
- Where is 6 Dimensions Capital located?
- 6 Dimensions Capital is headquartered in Grand Cayman, US.
Co-investors · 17
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Dimension is a multistage investment firm that partners with companies working at the intersection of science and compute.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Sequoia Capital is a venture capital firm that partners with founders to build technology companies.
Lightspeed Venture Partners is a global venture capital firm that backs founders from Seed through Series F and beyond, emphasizing deep, immersive partnerships with the companies it invests in.
Operator Partners is an investment firm run by operators that invests its own capital in technology companies from inception through Series B.
AlleyCorp is an early-stage investor and incubator based in New York that builds and backs companies across enterprise, consumer, healthcare, and deep tech sectors.
Octopus Ventures is a founder-focused European venture capital firm that backs mission-driven startups across seven core sectors, investing from idea stage through growth with a focus on pre-seed to Series A.
Northpond Ventures is a venture capital firm based in Bethesda, Maryland that invests in life sciences, technology, and related sectors.
▶5 more co-investors
SuperSeedAndreessen HorowitzFounders FundDCVC (Data Collective)Novo Holdings
Firms observed investing alongside 6 Dimensions Capital, from public investor directories. Shared companies are the overlap with 6 Dimensions Capital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.